Nucleix Announces Recent Advancements in Early Lung Cancer Detection Program

SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced recent advances in its EpiCheck^® Next Generation Sequencing (NGS) platform and lung cancer detection program for early stage disease. The company also recently secured an additional $22 million in funding, as an extension to the previously announced $55 million financing, bringing the total capital raised in 2021 to $77 million, to rapidly advance the next generation of its highly sensitive lung cancer product and drive a multi-center prospective trial for clinical validation. Additionally, the company strengthened its leadership team with the appointment of Catherine Schnabel, Ph.D., as its chief scientific officer.